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A uniﬁed strategy for enantioselective total synthesis of all stereoisomers of the [2þ2] family of quad-
rigemine alkaloids is reported. In this approach, two enantioselective intramolecular Heck reactions are
carried out at the same time on precursors fashioned in four steps from either meso- or (þ)-chimo-
nanthine to form the two critical quaternary carbons of the peripheral cyclotryptamine rings of these
products. Useful levels of catalyst control are realized in either desymmetrizing a meso precursor or
controlling diastereoselectivity in elaborating C2-symmetric intermediates. None of the synthetic
quadrigemines are identical with alkaloids isolated previously and referred to as quadrigemines A and E.
In addition, we report improvements in our previous total syntheses of (þ)- or ()-quadrigemine C that
shortened the synthetic sequence to 10 steps and provided these products in 2.2% overall yield from
tryptamine.
 2015 Published by Elsevier Ltd.1. Introduction
Alkaloids composed of multiple 1,2,3,3a,8,8a-hexahydropyrrolo
[2,3-b]indole (cyclotryptamine or pyrrolidinoindoline) units have
been isolated from a variety of natural sources, including bacteria,
fungi, plants, and amphibians (Fig. 1).1 In the predominant family of
these alkaloids, cyclotryptamine units are joined at their benzylic
C3a carbon to generate dimers, trimers, and higher-order oligo-
mers. In this linkage, two types of quaternary stereogenic centers
are produced: (a) vicinal quaternary carbons joining benzylic (C3a)
quaternary stereocenters of two cyclotryptamine units, and (b)
aryl-substituted quaternary carbons linking the peri (C7) carbon ofx: þ1 949 824 3866; e-mail
l Research, Global Discovery
2139, USA.
versity of Rochester, RC Box
nt LLC, Medicinal Chemistry
121, USA.
r Cambridge, MA 02142, USA.
berlin Drive, Suite 100, San
S. M.; et al., Tetrahedron (201one pyrrolidinoindoline unit and the benzylic quaternary stereo-
center of another. Both types of quaternary stereocenters present
formidable challenges for stereocontrolled synthesis. As a result,
when our efforts in this area began in 1995, no stereocontrolled
methods were available for linking cyclotryptamine fragments at
C3a.2 In the intervening years, this challenging problem in total
synthesis has been addressed by a number of researchers andmany
imaginative methods are currently available.2,3 Nonetheless, ster-
eocontrolled total synthesis of the more complex members of this
group remains largely an unmet challenge.4
The ﬁrst cyclotryptamine alkaloids containing four tricyclic
units, quadrigemines A and B, were reported by Perry and Smith in
1978 from the leaves of Hodgkinsonia frutesecens.5,6 Analysis of
quadrigemine A revealed a base peak of m/z 344 corresponding to
half the molecular weight of quadrigemine A along with ions m/z
345 and 690 in the EI mass spectrum. In comparison, quadrigemine
B showed a parent ion ofm/z 516, along with ionsm/z 690, 517, and
172. The difference in fragmentation patterns corresponds to the
location of the labile s-bond connecting the 3a0e3a00-vicinal qua-
ternary carbon centers of the chimonanthine subunit.7 This frag-
mentation pattern has been used to designate the two groups of
constitutional isomers: the [2þ2] and [3þ1] quadrigemine alka-
loids (Fig. 1).85), http://dx.doi.org/10.1016/j.tet.2015.02.080
Fig. 1. A pyrrolidinoindoline fragment and the connectivity of the chimonanthine and quadrigemine alkaloids.
S.M. Canham et al. / Tetrahedron xxx (2015) 1e132Quadrigemines A,5 C,9 and E10 are the three reported members
of the [2þ2] quadrigemine family. The complex NMR spectra and
amorphous nature of these higher-order polypyrrolidinoindoline
alkaloids has made determination of their three-dimensional
structures particularly difﬁcult. The relative and absolute conﬁgu-
ration of only quadrigemine C (1) is known with certainty (Fig. 2).
Sevenet, who initially isolated quadrigemine C from an extract of
Psychotria oleoides found in New Caledonia,9a provided evidence for
the R absolute conﬁguration of the two outer quaternary carbons of
1 by chemical correlation with hodgkinsine, whose absolute and
relative conﬁguration had been determined by single-crystal X-ray
analysis.9b,11 However, rigorous proof of the absolute conﬁguration
of the central chimonanthine unit was not secured until the
enantioselective total synthesis of ()-quadrigemine C was re-
ported by our group in 2002.4 The optical rotations reported for
quadrigemines A, C, and E in alcoholic solvents ([a]D A, þ32
(EtOH);5 C, þ40 (MeOH);9d E, þ33 (EtOH))10 are similar; suggesting
that these alkaloids, which were isolated by different laboratories,
could be identical.12 Resolving this issue from the published NMR
characterization data is impossible, because of differences in the
reported NMR solvent and spectrometer ﬁeld strength. Even if di-
rectly comparable data were available for evaluation, the presence
of several interconverting low-energy conformations of these al-
kaloids results in broad peaks on the NMR time-scale at 298 K.Fig. 2. Structure of quadrigemin
Please cite this article in press as: Canham, S. M.; et al., Tetrahedron (201Attempts to coalesce these signals at elevated temperatures are
typically compromised by the lability of s-bond connecting the
vicinal quaternary carbons.7 Cooling the NMR sample can result in
enhanced resolution of the major conformers, as is the case for
quadrigemine C;4,9c however, fully analyzing these complex spectra
is challenging. Quadrigemines A and E, if different from quad-
rigemine C, could be one of six C2-symmetric stereoisomers (5, 6, 7
and their enantiomers, Fig. 2). Overall there are 10 possible [2þ2]
quadrigemine stereoisomers: 4 enantiomeric pairs and 2 meso
compounds (Fig. 2).
In an attempt to clarify the structures of quadrigemines A and E,
we initiated stereocontrolled total syntheses of the remaining
chiral members of the [2þ2] quadrigemine alkaloid family.
Moreover such an investigation would allow us to investigate the
degree of catalyst control achieved in enantioselective Heck cy-
clizations carried out with C2-symmetric intermediates; in our
original total synthesis of quadrigemine C (1), the pivotal enan-
tioselective cyclizations were realized with a meso precursor.
During these studies, several improvements to our original syn-
thesis of quadrigemine C were attained, allowing the synthetic
route to be shortened and the overall yield improved. Finally, with
access to an expanded group of [2þ2] quadrigemines, the effect of
relative and absolute conﬁguration on their antitumor activity was
evaluated.e C and six stereoisomers.
5), http://dx.doi.org/10.1016/j.tet.2015.02.080
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2.1. Inside-out approach to the [2D2] quadrigemines
In the approach we developed to synthesize members of the
[2þ2] family of quadrigemines, the outer two pyrrolidinoindoline
fragments are elaborated simultaneously on a functionalized chi-
monanthine core (Scheme 1). The formation of decacyclic dioxin-
dole A by double enantioselective intramolecular Heck cyclization
of dibutenanilide B is the pivotal step in this sequence.13 The Heck
cyclization precursor B is formed by a double Stille coupling of
a chimonanthine diiodide C with 2 equiv of stannane 8, an in-
termediate that contains all the heavy atoms of a cyclotryptamine
fragment. The natural products meso-chimonanthine and its
enantiopure C2-symmetric stereoisomers, which are now readily
available by stereocontrolled chemical synthesis,14,15 serve as the
starting point of the synthetic sequence.H
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Scheme 1. Retrosynthetic analysis: an inside-out synthetic strategy.
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Scheme 2. Optimized double Stille cross coupling.2.2. Enantioselective synthesis of [2D2] quadrigemines hav-
ing a meso core
In our initial synthesis of quadrigemine C,4meso-chimonanthine
(9) was prepared from oxindole and isatin in 13 steps and w30%
overall yield by a stereocontrolled sequence that we had deﬁned
previously.14b To expedite access to larger quantities of meso-chi-
monanthine (9), we have since adopted the non-stereocontrolled
oxidative dimerization method reported by Takayama andPlease cite this article in press as: Canham, S. M.; et al., Tetrahedron (201co-workers.16 This method involves the oxidative dimerization of
Nb-carbomethoxytryptamine with phenyliodine(III) bis(tri-
ﬂuoroacetate) and a subsequent reduction with Red-Al to gener-
ate meso-chimonanthine (9) in two steps and 20e30% yield. Willis
and co-workers recently improved this procedure by enhancing
overall scalability and puriﬁcation of product 9.17 Utilizing our
previously published procedure, meso-chimonanthine diiodide 10
was prepared from meso-chimonanthine in three steps and 66%
overall yield by di-Boc protection, di-ortho-iodination, and removal
of the Boc groups (Scheme 2).4In our ﬁrst generation synthesis, the Stille cross coupling of
meso-diiodide 10with 3 equiv of stannane aryl triﬂate 8 to provide
themeso-dibutenanilide 11was achieved using a catalyst system of
Pd2dba3$CHCl3, tri-2-furylphosphine and CuI in 1-methyl-2-
pyrrolindoline (NMP).4,18 This Stille coupling was sluggish, re-
quiring long reaction times (>36 h) at room temperature, and
provided variable yields of 11 (55e71%). In the hope of both ac-
celerating the rate of the reaction and improving the overall yield,
several additional conditions for accomplishing this double cross
couplingwere investigated. Attempts to accelerate the reaction rate
by increasing the reaction temperature were thwarted by slow
decomposition of the aryl triﬂate functionality of stannane triﬂate
8. The use of ﬂuoride ion (CsF) to accelerate the reaction did not
have a substantial effect on improving the overall conversion.19 The
use of copper(I) thiophene-2-carboxylate (CuTC),20 or CuTC in ad-
dition to [Ph2PO2][NBu4]21 did accelerate the reaction rate, but did
not improve the yield. After further experimentation, a Stille cou-
pling procedure reported by Corey and co-workers using
Pd(PPh3)4/CuCl/LiCl was found to be optimal.22 Thus, reaction of
meso-diiodide 10 with 3 equiv of stannane aryl triﬂate 8, 0.5 equiv
of Pd(PPh3)4, 5 equiv of CuCl, and 6 equiv of LiCl in DMSO at room
temperature for 20 h providedmeso-dibutenanilide 11 in 96% yield.
As the outer pyrrolidinoindolines of quadrigemine C (1) have
the same absolute conﬁguration, our strategy was to utilize an
enantioselective intramolecular Heck reaction to access the desired
C1-symmetric dioxindole stereoisomer using a two-directional
synthesis strategy.23 In accordance with the Horeau principle,
a double enantioselective transformation has the potential to am-
plify the enantiopurity of the product over that provided by a single
enantioselective transformation.24 Although the overall yield of the
desired product is diminished, the product’s enantiomeric purity
should by equal to the square of the enantioselectivity of a single
reaction.5), http://dx.doi.org/10.1016/j.tet.2015.02.080
Table 1
Optimization of the double enantioselective Heck cyclization ofmeso-dibutenanilide
11
Entry Conditionsa Solvent ds ratio (12/13/14)b % ee 12b
1 (R)-BINAP THF 2.8:1.7:1.0 65
2 (R)-BINAP DMA 2.5:1.0:1.1 64
3 (R)-BINAP MeCN 3.5:1.7:1.0 80
4 (R)-BINAP PhMe 3.1:2.7:1.0 54
5c (S,S)-BDPP THF 2.4:1.0:1.5 35
6 (R)-Tol-BINAP THF 7.2:2.0:1.0 85
7 (R)-Tol-BINAP DMA 6.7:1.2:1.0 81
8 (R)-Tol-BINAP NMP 5.6:1.2:1.0 80
9 (R)-Tol-BINAP NMP 5.1:1.7:1.0 79
10 (R)-Tol-BINAP MeCN 9.3:2.0:1.0 90
a Pd(OAc)2 (50 mol %), 100 mol % phosphine ligand, 4 equiv 1,2,2,6,6-
pentamethylpiperidine (PMP), 80 C.
b Ratio determined by HPLC.
c Compound ent-12 was formed preferentially.
S.M. Canham et al. / Tetrahedron xxx (2015) 1e134Several conditions were examined to optimize the double
enantioselective Heck cyclization of meso-dibutenanilide 11
(Scheme 3, Table 1). Of the diphosphine ligands screened, (R)-tol-
BINAP in MeCN provided superior diastereo- and enantioselection,
providing pentacyclic dioxindole 12 and its twomeso stereoisomers
in a ratio of 9.3:2.0:1.0. The C1-symmetric product 12 (62%, 90% ee)
and themeso products 13 and 14 (14% and 7%, respectively)25 were
separated by preparative HPLC. The related enantioselective Heck
cyclization employed in the enantioselective synthesis of the
nonacyclic cyclotryptamine alkaloids hodgkinsines A and B from
meso-chimonanthine gave a 1:1 ratio of these products in high
yield and 79 and 83% ee.26,27 As the observed enantiomeric purity
of the C1-symmetric product 12 (90% ee) is somewhat less than the
predicted (98% ee) from the results in the hodgkinsine series, it can
be inferred that the two enantioselective intramolecular Heck re-
actions are not completely independent. It is important to note that
representing these molecules in two dimensions is deceiving. This
decrease in enantioselectivity from the predictedmodel most likely
results from stereoinduction across the meso-chimonanthine
backbone during the second Heck cyclization. A sense that such
interactions would be possible can be gleaned from a three-
dimensional model of quadrigemine C (Fig. 3). Carrying out the
cyclization of ditriﬂate 11 under identical conditions using (S)-
rather than (R)-BINAP gave dioxindole ent-12 in 80% yield; the
higher selectivity in forming the C1-symmetric product in this
double enantioselective Heck reaction suggests that catalyst andFig. 3. Model of a low-energy conformation of quadrigemine C.28
Scheme 3. Double enantioselective Heck cyclization of meso-dibutenanilide 11 (one of
the meso stereoisomers has the S,S,R,R absolute conﬁguration and the other the R,S,R,S
absolute conﬁguration).
Please cite this article in press as: Canham, S. M.; et al., Tetrahedron (201substrate control are matched with the catalyst formed from (S)-
BINAP.
In our original synthesis of quadrigemine C, diene disul-
fonamide 12 was hydrogenated at 100 psi using Pd(OH)2/C in 10:1
EtOH/MeOH at 80 C to saturate the two double bonds.4 These
conditions often resulted in yields of the tetrahydro product 15 that
varied depending upon the batch of substrate and catalyst.29 Since
our initial report, we discovered that including 8 equiv of K2CO3
resulted in enhanced reproducibility for this transformation, which
we attribute to preventing any acid-catalyzed decomposition.30,31
Additionally, increasing the hydrogen pressure to 1000 psi in
EtOH at 80 C helped to ensure full conversion. Using this pro-
cedure,12 reproducibly was transformed to its tetrahydro congener
in yields of 90e95% (Scheme 4). Exposure of this unpuriﬁed in-
termediate to a large excess of Na (50 equiv) in THF/NH3 containing
4 equiv of tert-butanol for 20 min at78 C, followed by quenching
with NH4Cl and HPLC puriﬁcation afforded ()-quadrigemine C (1).
Modiﬁcation of our previous conditions by the incorporation of
tert-butanol32 led to signiﬁcant improvements in reproducibility,
reliably yielding ()-quadrigemine C in 22e24% for the two steps.
5), http://dx.doi.org/10.1016/j.tet.2015.02.080
Scheme 4. Completion of an optimized total synthesis of quadrigemine C.
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S.M. Canham et al. / Tetrahedron xxx (2015) 1e13 5The improvements made in this second-generation synthesis of
()-quadrigemine C shortened the synthetic sequence to 10 steps
and provided ()-quadrigemine C (1), [a]D23 e67 (c 0.2, CHCl3) and
[a]D23 e30 (c 0.2, EtOH), in 2.2% overall yield from tryptamine.
Synthetic ()-quadrigemine C showed physical properties (1H
NMR, 13C NMR, HRMS) consistent with those of the natural
product,9aed and was indistinguishable from an authentic sample
by HPLC and CD analysis.33,34 Moreover, heating a sample of
()-quadrigemine C at 100 C in the presence of dilute aqueous
acetic acid gave synthetic ()-psycholeine (16) in 38% yield, which
showed 1H NMR and 13C NMR spectra identical to those reported
for the natural product.9aec Using the optimized procedures de-
scribed herein, ent-(þ)-quadrigemine C (2), [a]D23 þ70 (c 0.12,
CHCl3) and [a]D23 þ19 (c 0.15, EtOH), as well as the two meso-
quadrigemine congeners 3 and 4 were prepared in an identical
fashion (see summary in Table 3).NMeTs
19
Scheme 5. Synthesis of the Heck cyclization precursor in the C2-symmetric series.
Table 2
Diastereoselective double Heck cyclization in the C2-symmetric series
Entry Conditionsa Solvent ds ratio (20/21; C2/C1)b
1 rac-Tol-BINAP NMP 1.0:2.3
2 (R)-Tol-BINAP NMP 4.3:1.0
3 (R)-Tol-BINAP MeCN 3.0:1.0
4 (R)-Tol-BINAP THF 2.5:1.0
5 (R)-Tol-BINAP PhMe 1.0:2.3
a Pd(OAc)2 (50 mol %), 100 mol % phosphine ligand, 4.0 equiv 1,2,2,6,6-
pentamethylpiperidine (PMP), 80 C.
b ratio determined by HPLC.2.3. Enantioselective total synthesis of [2D2] quadrigemines
having a C2-symmetric chimonanthine core
The starting material for our studies in this series was (þ)-chi-
monanthine (17), which we prepared in gram quantities from
a-methoxycarbonyl-L-tryptophanmethyl ester using the eight-step
biomimetic sequence developed by Movassaghi and co-workers.14c
The necessary C2-symmetric diiodide 18 was synthesized, as pre-
viously optimized in the meso-chimmonanthine series, by di-Boc
protection of the aniline nitrogens, di-ortho-iodination, and re-
moval of the Boc groups to provide C2-symmetric diiodide 18 in 72%
yield. The di-Stille cross coupling of diiodide 18 with stannane 8
using the recently optimized conditions provided C2-symmetric
dibutenanilide 19 in 98% yield (Scheme 5).
We turned to examine the double enantioselective Heck cycli-
zation in the C2-symmetric series, wherein the chiral substrate
would inﬂuence diastereoselectivity.31,35 To examine the inherent
substrate bias, the double enantioselective Heck cyclization of
ditriﬂate 19 was carried out initially using rac-tol-BINAP, which
resulted in modest substrate control to give the C2- and C1-sym-
metric dioxindole products 20 and 21 in a 1.0:2.3 ratio. Utilizing the
catalyst generated from 0.5 equiv Pd(OAc)2, 1.0 equiv of (R)-tol-
BINAP, and 4 equiv of 1,2,2,6,6-pentamethylpiperidine (PMP) at
80 C, various solventswere evaluated. Adecrease in solventpolarity
from N-methylpyrrolidinone (NMP) to THF resulted in a decrease in
diastereoselectivity (entries 2e4, Table 2). To some surprise, dia-
stereoselection was inverted in toluene, giving the C1-symmetricPlease cite this article in press as: Canham, S. M.; et al., Tetrahedron (201stereoisomer 21 as the major product. The combined yield of the
decacyclic dioxindole products 20 and 21 produced in NMP was
lower (58%) than we had anticipated. Analysis of the crude product
mixture by mass spectrometry identiﬁed the formation of byprod-
ucts in which one of the pyrrolidinoindoline nitrogens had been
acetylated. This product is a likely culprit of the decreased selectivity
and undoubtedly arose from the formation of acetic anhydride
during the reduction of Pd(OAc)2 by the phosphine ligand.36 In-
clusion of 10 equiv of N-methyl-p-anisidine as a scavenger for Ac2O
diminished formation of the acetylated byproducts, providing the
C2-symmetric dioxindole 20 and its C1-symmetric stereoisomer 21
in 4.3:1 ratio and 79% combined yield. Identical Heck cyclization of5), http://dx.doi.org/10.1016/j.tet.2015.02.080
S.M. Canham et al. / Tetrahedron xxx (2015) 1e13619 using Pd-(S)-tol-BINAP afforded C2-symmetric (S,R,R,S) dioxin-
dole 22 and dioxindole 21 in a 2:1 ratio and 81% yield (Scheme 6).
Thediastereomeric dioxindole products productswere separatedby
silica gel chromatography and subsequently processed in-
dependently to their respective [2þ2] quadrigemines.Scheme 6. Diastereoselective double Heck cyclization of C2-symmetric dibutenanalide 19.Utilizing the procedures developed during our optimized total
synthesis of quadrigemine C (1), pentacyclic dioxindole products
20e22 were hydrogenated (1000 psi) with Pd(OH)2/C in EtOH at
80 C. Subsequent exposure of the resulting tetrahydro products to
a large excess of sodium (50 equiv) in THF/t-BuOH/NH3 at 78 C
for 20 min, followed by quenching with NH4Cl provided the re-
spective [2þ2] quadrigemine products 5e7, in 23e29% yield for the
ﬁnal two steps. The yields of the ﬁnal steps in the total syntheses of
the quadrigemine stereoisomers prepared in this study and the
optical rotations at the sodium D line of the quadrigemine products
are summarized in Table 3. The CD spectra of synthetic quad-
rigemines 1, 2, 5e7 are shown in Fig. 4.Table 3
Yield of the ﬁnal two steps in the synthesis of [2þ2] quadrigemines and their optical
rotations
Starting
material
Product Yield
(over two steps) (%)
[a]Da
12 1 (R,S,R,R)-Quadrigemine C 22e24 30 (67)b
ent-12 2 (S,R,S,S)-ent-Quadrigemine C 24 þ20 (þ70)b
13 Major meso-Quadrigeminec,e 40 d
14 Minor meso-Quadrigemined,e 16 d
20 7 (R,R,R,R) 23 þ277
21 6 (S,R,R,R) 29 þ140
22 5 (S,R,R,S) 29 þ231
a [a]D taken in EtOH.
b [a]D taken in CHCl3.
c The dodecacyclic product resulting from transformation of the majormeso Heck
product 13.
d The dodecacyclic product resulting from transformation of the minormesoHeck
product 14.
e The relative conﬁguration could not be conﬁrmed, the product is either meso-
quadrigemine 3 or 4.The optical rotation data and 13C NMR spectra for the syn-
thetic quadrigemines 5e7 conﬁrm that these C2-symmetic [2þ2]
quadrigemines are not identical to natural quadrigemines A and
E.37 Moreover, HPLC comparison of these products with a crude
isolate of Psychotria muscosa showed that these syntheticPlease cite this article in press as: Canham, S. M.; et al., Tetrahedron (201quadrigemines were not identical to the structurally uncharac-
terized higher-order polypyrrolidindoline alkaloids identiﬁed in
this sample by Verotta and co-workers.38,39 These ﬁndings sug-
gest that quadrigemines A and E could be identical to quad-
rigemine C.2.4. Antitumor evaluation
A diversity of biological activitiesdantiviral, antibacterial, anti-
fungal, and anticandidaldare described for quadrigemine alka-
loids.1c In addition, selected quadrigemines are reported to be
analgesics,31,38,40 antagonists of the somatostain receptor (SRIF),9b
inhibitors of human platelet aggregation,41 and to display cyto-
toxic activity against solid and blood tumors.42 To gain some insight
into the relationship between the three-dimensional structures of
higher-order polypyrrolidinoindoline alkaloids and their antitumor
activity, the in vitro cytotoxicities of the [2þ2] quadrigemines
prepared in this study, and several additional polypyrrolindoline
alkaloids prepared in our laboratories (depicted in Fig. 5), were
determined against two invasive cancer cell lines: DU145 (human
prostate cancer) and A2058 (human melanoma). Several trends
emerge from the cytotoxicity data summarized in Table 4: (a) in
general, cytotoxicity increases as a function of molecular weight
(increasing number of pyrrolidinoindoline units); only one dodec-
acyclic alkaloid (the minor meso-quadrigemine 4, entry 3) was less
active than the nonacyclic alkaloids (entries 7e11). (b) Relative
conﬁguration of higher-order polypyrrolidinoindolines makes only
a minor contribution to cytotoxicity. For example, ()-quad-
rigemine C is only 2e4-fold more active than the other [2þ2]
quadrigemine alkaloids. (c) ()-Psycholeine (16), the isomer of
()-quadrigemine C having a calycanthine core, showed little cy-
totoxicity (entry 7). The ﬁrst two of these trends are in accord with
cytotoxicity data reported previously for a few cyclotryptamine
alkaloids.42
3. Conclusion
The inside-out strategy (Scheme 1) that we ﬁrst introduced in
2002 to synthesize ()-(1) and (þ)-quadrigemine C (2) is utilized in
this investigation to prepare all potential stereoisomers of dodec-
acyclic quadrigemines having chimonanthine cores (Fig. 2). As
a prelude to these studies, two stepsdthe double Stille cross cou-
pling to introduce the heavy atoms of the peripheral cyclotrypt-
amine rings and the subsequent catalytic hydrogenationewere5), http://dx.doi.org/10.1016/j.tet.2015.02.080
Fig. 4. Circular dichroism of [2þ2] quadrigemines. All data taken w2.9104 M in EtOH.
Table 4
Cytotoxic activity against prostate cancer (DU145) and melanoma (A2508) cell lines
(IC50)a
Entry Compound DU145 (mM) A2058 (mM)
1 ()-Quadrigemine C (1) 2.2 1.7
2 meso-Quadrigeminea,c 4 5
3 meso-Quadrigemineb,c >10 >10
4 (S,R,R,S)-Quadrigemine (5) 8.8 4.1
5 (S,R,R,R)-Quadrigemine (6) 4.7 3.5
6 (R,R,R,R)-Quadrigemine (7) 5.0 4.1
7 ()-Psycholeine (16) >10 >10
8 ()-Hodgkinsine 7.2 7.2
9 ()-Hodgkinsine B 8.0 8.1
10 ()Idiospermuline >10 >10
11 ()-epi-Idiospermuline >10 >10
12 meso-Chimonanthine (9) >10 >10
13 ()-Chimonanthine (ent-17) >10 >10
14 ()-Calycanthine >10 >10
a The dodecacyclic product resulting from transformation of the majormeso Heck
product 13.
b The dodecacyclic product resulting from transformation of the minormesoHeck
product 14.
c The relative conﬁguration could not be conﬁrmed, the product is either meso-
quadrigemine 3 or 4.
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more robust. The second-generation total synthesis of natural
()-quadrigemine C (1) reported herein was accomplished in 10
steps and 2.2% overall yield from tryptamine. This short enantio-
selective total synthesis, and the other concise constructions of
quadrigemine stereoisomers we report, are testaments to the
power of two-directional synthesis strategies23 and the utility ofPlease cite this article in press as: Canham, S. M.; et al., Tetrahedron (201catalytic enantioselective transformationsdin this case intra-
molecular Heck reactions13dto stereoselectively generate struc-
turally intricate polycyclic molecules. The total syntheses reported
herein are rare examples of using two-directional strategies to
stereoselectively elaborate cyclic molecules.43
This total synthesis study showed that the previously reported
alkaloids referred to as quadrigemines A5 and E10 are not identical
to any of the synthetic quadrigemine stereoisomers, andmost likely
are the same as quadrigemine C. In addition, investigations of the
in vitro antitumor activities of products prepared in this study
showed that the relative conﬁguration of the [2þ2] family of
quadrigemines inﬂuences cytotoxicity in only a minor way.
4. Experimental section
4.1. General
Experimental procedures and characterization data for the prep-
aration of compounds 1, 8,11e15 have been reported previously.4
4.2. Enantioselective total synthesis of quadrigemine C (1)
and ent-quadrigemine C (ent-1)
4.2.1. meso-Dibutenanilide 11. Diiodide 10 (262 mg, 0.44 mmol)
and stannane 8 (1.14 g, 1.31 mmol) were combined in a round
bottom ﬂask and azeotroped to dryness with dry THF (36mL). The
mixture was placed under vacuum (1.0 mmHg) for 30 min and then
pumped into an inert atmosphere (N2) drybox. A stirbar followed
by Pd(PPh3)444 (252mg, 0.219mmol), LiCl (111mg, 2.60mmol), and5), http://dx.doi.org/10.1016/j.tet.2015.02.080
S.M. Canham et al. / Tetrahedron xxx (2015) 1e138CuCl (216 mg, 2.19 mmol) were added to the ﬂask and the mixture
was suspended in dry DMSO (15 mL). The ﬂask was capped and
stirred at room temperature in the drybox for 20 h. After removing
the ﬂask from the drybox, the black solution was partitioned be-
tween 5% v/v aqueous solution of NH4OH (20 mL) and EtOAc
(30 mL) and the aqueous phase was extracted with EtOAc
(315 mL). The combined organic layers were washed consecu-
tively with water and brine. The organic layer was dried over
MgSO4, ﬁltered, and concentrated under reduced pressure. The
dark residue was puriﬁed by ﬂash column chromatography (10%
KF/SiO245 100% CH2Cl2/10:1 CH2Cl2/MeOH); product 11 (635 mg,
96%) elutes with 3e5% MeOH in CH2Cl2 as a brown foam, which
showed 1H and 13C NMR spectra identical to those reported.4
4.2.2. Double enantioselective Heck cyclization of meso-dibutena-
nalide 11. A sample of ditriﬂate 11 (150 mg, 0.100 mmol) was
azeotroped to dryness in benzene (32 mL) in a sealable Schlenk
tube and placed under vacuum (1.0 mm) for 1 h. To the Schlenk
ﬂask were added a stirbar, Pd(OAc)2 (23 mg, 0.10 mmol), and (R)-
tol-BINAP (0.140 g, 0.200 mmol). The ﬂask was evacuated and
backﬁlled with N2 (3). Dry MeCN (2 mL) and 1,2,2,6,6-
pentamethylpiperidine49 (73 mL, 0.40 mmol) were added and the
reaction mixture was degassed using the freezeepumpethaw
technique (three cycles, liquid N2 cooling bath, 0.1 mmHg, back-
ﬁlled with N2). The heterogeneous brown-red mixture was then
heated to 80 C for 16 h. After cooling to room temperature, the
deep red solution was partitioned between a 20% w/w aqueous
solution of NaCN (10 mL) and EtOAc (10mL). The aqueous layer was
extractedwith EtOAc (320mL). The combined organic layers were
washed with water and brine. The organic layer was dried over
Na2SO4, ﬁltered, and concentrated under reduced pressure. The
residue was puriﬁed by column chromatography (SiO2: 100:0
CH2Cl2/97:3 CH2Cl2/MeOH/94:5:1 CH2Cl2/MeOH/
NH4OH/89:10:1 CH2Cl2/MeOH/NH4OH) to provide a mixture of
12, 13, and 14 in a 9:2:1 ratio (ratio determined by reverse-phase
HPLC analysis). The three diastereomers could be further puriﬁed
by preparative reverse-phase HPLC (Phenomenex Gemini-NX,
25021.2 mm), 80:20 MeCN/H2O (1% NH4OH), 25 mL/min, UV
detection at 254 nm; to afford 74 mg (62%) of 12 (tR¼30.9 min),
17 mg (14%) of 13 (tR¼37.6 min), and 8 mg (7%) of 14 (tR¼23.7 min)
as colorless foams.
4.2.2.1. (R,R,S,R)-Isomer 12.4 [a]D28 e60, [a]57728 e62, [a]54628 e72,
[a]43528 e153, [a]40528 e207 (c 0.25, CH2Cl2).
4.2.2.2. Major meso-isomer 13. 1H NMR (500 MHz, (CD3)2SO,
376 K) d 7.49 (d, J¼7.5 Hz, 4H), 7.35 (d, J¼7.8 Hz, 6H), 7.34e7.31
(m, 4H), 7.27e7.23 (m, 8H), 7.06e7.01 (m, 4H), 6.96 (d, J¼7.2 Hz,
2H), 6.79 (d, J¼7.8 Hz, 2H), 6.65 (d, J¼14.3 Hz, 2H), 6.41 (br s, 2H),
5.32 (d, J¼14.2 Hz, 2H), 4.97 (d, J¼15.4 Hz, 2H), 4.90 (d, J¼15.5 Hz,
2H), 4.25 (br s, 2H), 4.09 (s, 2H), 2.85 (s, 6H), 2.38 (s, 6H),
2.30e2.24 (m, 4H), 1.98e1.94 (m, 2H), 1.78e1.73 (m, 2H), 1.71 (s,
6H); 13C NMR (125 MHz, (CD3)2SO, 376 K) d 175.9 (C), 148.9 (C),
143.3 (C), 141.3 (C), 135.7 (C), 133.8 (C), 133.7 (C), 130.6 (C), 129.7
(CH), 129.3 (CH), 128.0 (CH), 127.6 (CH), 126.92 (CH), 126.88 (CH),
126.2 (CH), 126.0 (CH), 124.0 (CH), 122.7 (C), 122.0 (CH), 118.6 (C),
116.8 (CH), 110.0 (CH), 108.9 (CH), 82.3 (CH), 61.7 (C), 55.6 (C),
50.8 (CH2), 42.8 (CH2), 36.0 (CH2), 33.8 (CH3), 31.9 (CH3), 20.2
(CH3); IR (thin ﬁlm) 3358, 2934, 1706, 1610, 1467, 1355, 1162,
745 cm1; LRMS-ESI (m/z) [MþH]þ calcd for C72H70N8O6S2H
1207.5; found, 1207.5.
4.2.2.3. Minor meso-isomer 14. 1H NMR (500 MHz, (CD3)2SO,
376 K) d 7.42 (d, J¼7.8 Hz, 4H), 7.32e7.27 (m, 6H), 7.22 (br s, 14H),
6.97 (br s, 4H), 6.94 (d, J¼7.6 Hz, 2H), 6.70 (br s, 2H), 6.58 (d,Please cite this article in press as: Canham, S. M.; et al., Tetrahedron (201J¼14.3 Hz, 2H), 5.37 (d, J¼14.2 Hz, 2H), 4.98 (d, J¼15.8 Hz, 2H), 4.75
(d, J¼15.8 Hz, 2H), 2.90 (br s, 2H), 2.85 (s, 6H), 2.69e2.59 (m, 2H),
2.46 (s, 6H), 2.38e2.35 (m, 2H), 2.34 (s, 6H), 2.16e2.09 (m, 2H), 2.04
(br s, 4H), 1.82e1.79 (m, 2H); 13C NMR (125 MHz, (CD3)2SO, 376 K)
d 175.9 (C), 148.9 (C), 143.3 (C), 141.3 (C), 135.7 (C), 133.7 (C), 130.6
(C), 129.7 (CH), 129.3 (CH), 129.2 (CH), 128.0 (CH), 127.6 (CH), 126.9
(CH),126.5 (CH),126.2 (CH),125.9 (CH),124.0 (CH),122.7 (CH),122.1
(CH), 118.6 (C), 116.7 (C), 110.1 (CH), 108.9 (CH), 82.3 (CH), 61.7 (C),
55.6 (C), 50.8 (CH2), 42.8 (CH2), 36.0 (CH3), 33.8 (CH2), 31.8 (CH3),
20.3 (CH3); IR (thin ﬁlm) 3405, 2934, 1710, 1610, 1455, 1359, 1162,
748 cm1; LRMS-ESI (m/z) [MþH]þ calcd for C72H70N8O6S2H
1207.5; found, 1207.5.
4.2.3. (S,R,S,S)-Isomer (ent-12). Carrying out the double Heck cy-
clization in similar fashion using (S)-tol-BINAP and 77 mg
(0.051 mmol) ofmeso-dibutenanalide 11 gave as the major product
dioxindole ent-12 (51 mg, 83%): 1H NMR (500 MHz, (CD3)2SO,
376 K)46 d 7.49e7.45 (m, 4H), 7.36e7.30 (m, 8H), 7.27e7.19 (m,10H),
7.11 (br d, J¼6.4 Hz,1H), 7.06e6.97 (m, 5H), 6.90 (br d, J¼7.7 Hz,1H),
6.74 (br s, 2H), 6.65 (d, J¼15.0 Hz, 1H), 6.61 (d, J¼15.8 Hz, 1H), 6.47
(br s, 1H), 6.34 (br s, 1H), 5.42 (d, J¼14.3 Hz, 1H), 5.29 (d, J¼14.3 Hz,
1H), 5.05 (d, J¼15.8 Hz, 1H), 4.98 (d, J¼15.5 Hz, 1H), 4.85
(d, J¼15.6 Hz, 1H), 4.78 (d, J¼15.8 Hz, 1H), 4.40e4.10 (br s, 3H), 2.88
(s, 3H), 2.83 (s, 3H), 2.66 (br t, J¼6.7 Hz, 1H), 2.52e2.48 (m, 2H),
2.38 (s, 3H), 2.36 (s, 3H), 2.35e2.30 (m, 1H), 2.29e2.21 (m, 1H), 2.14
(s, 3H), 2.07e1.89 (m, 1H), 1.86e1.82 (m, 1H), 1.78e1.71 (m, 1H),
1.72 (s, 3H); 13C NMR (125 MHz, (CD3)2SO, 376 K) d 176.2 (C), 176.0
(C), 150.0 (C), 149.0 (C), 143.4 (C), 143.3 (C), 141.3 (C), 141.2 (C),
135.66 (C), 135.64 (C), 134.5 (C), 133.9 (C), 133.7 (C), 133.4 (br, C),
130.5 (CH), 130.4 (C), 129.8 (CH), 129.5 (CH), 129.24 (2 peaks, CH),
127.93 (CH), 127.92 (CH), 127.68 (CH), 127.65 (CH), 127.58 (CH),
127.0 (CH), 126.8 (CH), 126.7 (CH), 126.4 (CH), 126.1 (CH), 126.0
(CH), 125.95 (CH), 124.5 (CH), 124.2 (CH), 122.8 (CH), 122.6 (CH),
122.1 (C), 121.9 (C), 118.24 (br, 2 peaks, C), 117.3 (CH), 116.6 (CH),
110.0 (CH), 109.8 (CH), 108.99 (CH), 108.95 (CH), 82.2 (CH), 62.6 (C),
61.8 (C), 55.7 (C), 50.98 (CH2), 50.97 (CH2), 42.8 (CH2), 42.7 (CH2),
35.8 (br, 2 peaks, CH2), 34.3 (CH3), 33.8 (CH3), 31.79 (CH3), 31.75
(CH3), 20.25 (CH3), 20.23 (CH3); IR (thin ﬁlm) 3354, 2930, 1710,
1610, 1359, 1162, 745 cm1; LRMS-ESI (m/z) [MþH]þ calcd for
C72H70N8O6S2H 1207.5; found, 1207.5; [a]D23 þ68, [a]57723 þ69, [a]54623
þ79, [a]43323 þ157 (c 0.33, CH2Cl2).
4.2.4. ()-Quadrigemine C (1). The procedure for hydrogenation of
the enesulfonamide side chains and reductive cyclization for the
ultimate conversion of tetrahydro intermediate to ()-quad-
rigemine C that is reported herein (see the optimized general
procedures described for the preparation of (R,R,R,R)-quadrigemine
7) has been found to be more reproducible than the procedure
described previously.4 Using the optimized general procedure for
hydrogenation of the enesulfonamide side chains, tetrahydro de-
rivative 15 was prepared in >90% yield: [a]D28 e144, [a]57728 e154,
[a]54628 e177, [a]43528 e369, [a]40528 e492 (c 0.10, CH2Cl2). Reduction of
this intermediate with Na/NH3/t-BuOH gave ()-quadrigemine (C)
(8.3 mg, 24% overall yield from 12), [a]D23 e67 (c 0.2, CHCl3), HRMS-
ESI (m/z) [MþH]þ calcd for C44H50N8H 691.4236; found, 691.4232;
NMR and IR and optical rotation data were identical to those re-
ported previously.4
4.2.5. ent-(þ)-Quadrigimine C (2). Following the optimized general
procedure for hydrogenation of the enesulfonamide side chains,
104 mg of ent-12 was converted to tetrahydro derivative ent-15.
This product was then directly subjected to the optimized reductive
cyclization conditions to afford ent-(þ)-quadrigemine C (2) (14 mg,
24%); IR (thin ﬁlm) 3271, 3054, 2929, 2854, 2791, 1604, 1481,
1452 cm1; HRMS-ESI (m/z) [MþH]þ calcd for C44H50N8H 691.4236;5), http://dx.doi.org/10.1016/j.tet.2015.02.080
S.M. Canham et al. / Tetrahedron xxx (2015) 1e13 9found, 691.4226; [a]D23þ20, [a]57723 þ17, [a]54623 þ18, [a]43523 þ48 (c 0.15,
EtOH); [a]D23 þ70, [a]57723 þ67, [a]54623 þ60, [a]43523 þ110 (c 0.12, CHCl3).4.3. Synthesis of meso-[2D2] quadrigemines
4.3.1. Tetrahydro derivative of the major meso-dioxindole isomer
13. Following the optimized general procedure for hydrogenation
of the enesulfonamide side chains, tetrahydro-13 (28.4 mg,
0.024 mmol, 98% yield) was obtained as a colorless solid from
29.6 mg of 13. 1H NMR (500 MHz, (CD3)2SO, 396 K) d 7.50 (d,
J¼8.1 Hz, 4H), 7.33 (d, J¼7.6 Hz, 8H), 7.29e7.20 (m, 10H), 7.13 (d,
J¼6.9 Hz, 2H), 7.09 (t, J¼7.1 Hz, 2H), 7.00 (d, J¼7.7 Hz, 2H), 6.85 (d,
J¼7.7 Hz, 2H), 6.50 (br s, 2H), 6.43 (br s, 2H), 4.96 (d, J¼15.5 Hz,
2H), 4.85 (d, J¼15.5 Hz, 2H), 4.78 (s, 2H), 4.29 (s, 2H), 2.96 (dt,
J¼5.0, 12.6 Hz, 2H), 2.79 (br s, 2H), 2.70e2.66 (m, 2H), 2.61 (s, 6H),
2.53e2.51 (m, 2H), 2.44e2.40 (m, 2H), 2.38 (s, 6H), 2.35e2.25 (m,
2H), 2.10e2.07 (m, 2H), 1.90 (s, 6H), 1.80e1.77 (m, 2H); 13C NMR
(125 MHz, (CD3)2SO, 396 K) d 176.8 (C), 149.3 (C), 142.3 (C), 141.8
(C), 135.5 (C), 134.8 (C), 130.0 (C), 128.8 (CH), 127.8 (CH), 127.5
(CH), 127.1 (C), 126.9 (CH), 126.7 (CH), 126.1 (CH), 125.2 (CH), 123.8
(CH), 122.6 (CH), 121.9 (CH), 117.7 (C), 116.9 (CH), 108.7 (CH), 82.6
(CH), 61.7 (C), 53.2 (CH2), 50.9 (C), 45.1 (CH2), 42.9 (CH2), 35.9
(CH2), 34.1 (CH3), 33.8 (CH3), 31.6 (CH2), 20.0 (CH3); IR (thin ﬁlm)
3336, 3060, 2928, 2865, 2791, 1697, 1610, 1487, 1454, 1342 cm1;
LRMS-ESI (m/z) [MþH]þ calcd for C72H74N8O6S2H 1211.5; found,
1211.5.
4.3.2. Tetrahydro derivative of the minor meso-dioxindole isomer
14. Following the optimized general procedure for hydrogenation
of the enesulfonamide side chains, tetrahydro-14 (28.2 mg,
0.024 mmol, 94% yield) was obtained as a colorless solid from
31.2mg of dioxindole 14. 1H NMR (500MHz, (CD3)2SO, 396 K) d 7.45
(d, J¼8.2 Hz, 4H), 7.31 (d, J¼8.4 Hz, 4H), 7.27e7.21 (m, 8H), 7.18 (d,
J¼7.6 Hz, 2H), 7.07 (t, J¼7.4 Hz, 2H), 6.97 (d, J¼7.8 Hz, 2H), 6.71 (br d,
J¼7.2 Hz, 2H), 4.89 (d, J¼15.7 Hz, 2H), 4.78 (d, J¼15.7 Hz, 2H), 4.27
(br s, 2H), 2.95e2.83 (m, 4H), 2.80 (s, 10H), 2.70e2.67 (m, 4H),
2.66e2.63 (m, 2H), 2.61 (s, 6H), 2.41e2.33 (m, 10H), 2.27e2.23 (m,
2H), 2.21 (s, 4H), 1.86 (dd, J¼4.7 and 11.4 Hz, 2H); 13C NMR
(125 MHz, (CD3)2SO, 396 K) d 177.0 (C), 142.3 (C), 141.9(C), 135.6 (C),
134.6 (C), 129.5 (C), 129.8 (CH), 127.7 (CH), 127.2 (CH), 126.9 (C),
126.6 (CH), 126.5 (CH), 126.1 (CH), 125.2 (C), 124.3 (CH), 122.5 (CH),
121.7 (CH),117.43 (C),108.8 (CH), 82.0 (CH), 62.1 (C), 53.6 (CH2), 50.9
(C), 45.4 (CH2), 42.8 (CH2), 35.3 (CH2), 34.3 (CH3), 33.9 (CH3), 30.6
(CH2), 20.0 (CH3); IR (thin ﬁlm) 3328, 3060, 2926, 2851, 2789, 1695,
1611, 1488, 1466, 1343 cm1; LRMS-ESI (m/z) [MþH]þ calcd for
C72H74N8O6S2H 1211.5; found, 1211.5.
4.3.3. Major meso-quadrigemine isomer. Following the optimized
general reductive cyclization procedure, 21 mg (0.017 mmol) of
tetrahydro-13 was transformed to quadrigemine derived from the
major meso-dioxindole Heck product 13. The solid was puriﬁed by
preparative reverse-phase HPLC (Zorbax Extend C18,10021.2mm,
80:20MeOH/H2O (1% NH4OH),16mL/min, UV detection at 254 nm)
to afford 4.8 mg (40%) of the major meso-quadrigemine isomer
(NOTE: relative conﬁguration was not established; this product is ei-
ther meso-quadrigemine 3 or 4.) (tR¼9.7 min) as a colorless solid. 1H
NMR (500 MHz, (CD3)2SO, 376 K) d 7.43e7.22 (m, 7H), 6.92 (d,
J¼7.5 Hz, 3H), 6.4e6.5 (m, 2H), 6.17 (s, 2H), 5.65 (s, 3H), 5.13 (s, 1H),
4.96 (br s, 1H), 4.27 (d, J¼6.6 Hz, 2H), 3.22 (s, 2H), 3.76 (br s, 7H),
2.57 (d, J¼6.9 Hz, 2H), 2.50e2.11 (m,11H), 1.61 (s, 3H), 1.32e1.28 (m,
4H); 13C NMR (125 MHz, (CD3)2SO, 376 K) d 147.0 (C), 146.7 (C),
140.9 (CH), 134.3 (C), 129.1 (CH), 128.2 (CH), 127.0 (CH), 120.5 (CH),
120.1 (C), 118.7 (CH),107.4 (CH), 107.1 (CH),100.5 (C), 69.0 (CH), 60.6
(C), 58.0 (C), 54.0 (CH2), 48.0 (CH2), 37.7 (CH2), 37.2 (CH2), 28.2
(CH3), 22.9 (CH3); IR (thin ﬁlm) 3365, 2923, 2851, 1658, 1605, 1451,Please cite this article in press as: Canham, S. M.; et al., Tetrahedron (2011247, 1158, 1035, 744 cm1; HRMS-ESI (m/z) [MþH]þ calcd for
C44H50N8H 691.4236; found, 691.4244.
4.3.4. Minor meso-Quadrigemine isomer. Following the optimized
general reductive cyclization procedure, 45 mg (0.037 mmol) of
tetrahydro-14 was converted the quadrigemine derived from the
minor meso-dioxindole Heck product 14. The resulting solid was
puriﬁed by preparative reverse-phase HPLC (Zorbax Extend C18,
10021.2 mm, 80:20 MeOH/H2O (1% NH4OH), 10 mL/min, UV de-
tection at 254 nm) to afford 4.0 mg (16%) of minor meso-quad-
rigemine isomer (NOTE: relative conﬁguration was not established;
this product is either meso-quadrigemine 3 or 4.) (tR¼70.7 min) as
a colorless solid. 1H NMR (500 MHz, (CD3)2SO, 376 K) d 6.98e6.93
(m, 4H), 6.60 (app t, J¼7.1 Hz, 2H), 6.54 (d, J¼7.8 Hz, 2H), 6.35 (br s,
2H), 5.88 (br s, 2H), 5.71 (br s, 2H), 4.81 (s, 2H), 4.55 (br s, 2H), 3.55
(s, 2H), 2.96 (6H, br s), 2.66e2.58 (m, 4H), 2.50 (s, 4H), 2.08 (br s,
10H), 1.91e1.89 (m, 2H), 1.82e1.81 (m, 2H), 1.27 (s, 2H); 13C NMR
(125MHz, (CD3)2SO, 376 K) d 150.9 (C), 149.3 (C),133.0 (C),131.8 (C),
126.8 (CH), 124.4 (CH), 123.9 (CH), 122.6 (C), 121.5 (CH), 116.7 (CH),
115.1 (CH), 107.4 (CH), 85.1 (CH), 82.3 (CH), 61.8 (C), 59.6 (C), 51.1
(CH2), 37.8 (CH2), 36.3 (CH2), 34.8 (CH3), 34.3 (CH3); HRMS-ESI (m/
z) [MþH]þ calcd for C44H50N8H 691.4236; found, 691.4248; IR (thin
ﬁlm) 3271, 2926, 2854, 2791, 1674, 1604, 1486, 1448, 1253, 1246,
1154,1032, 743 cm1; HRMS-ESI (m/z) [MþH]þ calcd for C44H50N8H
691.4236; found, 691.4237.
4.4. Enantioselective total synthesis of [2D2] quadrigemines
having a C2-symmetric core
4.4.1. (R,R)-1,10-Dimethyl-1,2,3,8,8a,10,20,30,8,8a0-octahydro-1H,1H0-
[3a,3a0]bi[pyrrolo[2,3-b]indolyl]-8,80-dicarboxylic acid di-tert-butyl
ester (E1). Following the procedure employed in the meso series,4
a THF solution of sodium bis(trimethylsilyl)amide (15.3 mL,
30.6 mmol, 2 M) was added dropwise via syringe pump over 3 h to
a solution of (þ)-chimonanthine (2.95 g, 8.51 mmol),14c di-tert-
butyldicarbonate (Boc2O) (8.16 g, 37.4 mmol), and THF (130 mL) at
78 C. Upon completion of the addition the solution was main-
tained for 30min at78 C and then partitioned between saturated
aqueous NH4Cl (50 mL) and EtOAc (50 mL). The layers were sepa-
rated and the aqueous phase was extracted with EtOAc (350 mL).
The combined organic layers were washed with brine (50 mL),
dried over MgSO4, ﬁltered, and concentrated under reduced pres-
sure. The residue was puriﬁed by ﬂash column chromatography
(2:98/5:95 MeOH/EtOAc) to yield the di-Boc derivative E1 as
a colorless foam (4.07 g, 87%): 1H NMR (600 MHz, (CD3)2SO, 373 K)
d 7.29 (d, J¼7.9 Hz, 2H), 7.04 (d, J¼7.5 Hz, 2H), 6.98 (dd, J¼7.7, 0.9 Hz,
2H), 6.74 (t, J¼7.4 Hz, 2H), 2.71e2.67 (m, 2H), 2.47e2.44 (m, 2H),
2.44 (s, 6H), 2.38e2.30 (m, 2H), 2.10e2.06 (m, 2H), 1.57 (s, 18H); 13C
NMR (150 MHz, (CD3)2SO, 373 K) d 152.3 (C), 143.0 (C), 135.1 (C),
128.1 (CH), 123.1 (CH), 122.4 (CH), 115.4 (CH), 85.8 (CH), 81.1 (C),
61.1 (C), 52.9 (CH2), 37.6 (CH3), 34.4 (CH2), 28.5 (CH3); IR (thin ﬁlm):
2974, 2942, 2793, 1696, 1483, 1384, 1366, 1164 cm1; HRMS-ESI (m/
z) [MþH]þ calcd for C32H42O4N4H 547.3284; found, 547.3267; [a]D23
þ163, [a]57723 þ168, [a]54623 þ191, [a]43523 þ355 (c 0.66, CH2Cl2).
4.4.2. (R,R)-7,70-Diiodo-1,10-dimethyl-1,2,3,8a,10,20,30,8a0-octahydro-
[3a,3a0]bi[pyrrolo[2,3-b]indolyl]-8,80-dicarboxylic acid di-tert-butyl
ester (E2). Following the procedure employed in the meso series,4
a cyclohexane solution of s-BuLi (23.5 mL, 23.0 mmol, 0.98 M)
was added dropwise over 1.5 h maintaining an internal tempera-
ture below 70 C to a solution of dicarbamate E1 (2.79 g,
5.10 mmol), N,N,N0,N0-tetramethylethylenediamine47 (TMEDA)
(4.55 mL, 30.1 mmol), and Et2O (51 mL) at 78 C. The solutionwas
aged at 78 C for 45 min. Then, a solution of diiodoethane (14.5 g,
51.0 mmol) and Et2O (51 mL) was added dropwise by syringe. The
resulting solution was maintained at 78 C for 10 min, then
5), http://dx.doi.org/10.1016/j.tet.2015.02.080
S.M. Canham et al. / Tetrahedron xxx (2015) 1e1310warmed to 0 C and maintained at 0 C for 3 h. The mixture was
partitioned between saturated aqueous Na2S2O4 (50 mL), saturated
aqueous NaHCO3 (50 mL), and EtOAc (50 mL). The phases were
separated and the aqueous layer was extracted with EtOAc
(350 mL). The combined organic layers were washed with brine
(100 mL) dried over MgSO4, ﬁltered, and concentrated under re-
duced pressure. The residue was puriﬁed by ﬂash column chro-
matography (2:1/0:100 hexane/EtOAc) to provide diiodide E2 as
a beige solid (3.11 g, 84%): 1H NMR (600 MHz, (CD3)2SO, 373 K)
d 7.62 (d, J¼7.9 Hz, 2H), 7.06 (d, J¼7.5 Hz, 2H), 6.74 (t, J¼7.7 Hz, 2H),
5.32 (s, 2H), 2.65e2.62 (m, 2H), 2.21e2.18 (m, 2H), 2.05e2.02 (m,
2H), 1.79e1.75 (m, 2H), 1.59 (s, 18H); 13C NMR (150 MHz, (CD3)2SO,
373 K) d 152.2 (C), 146.6 (C), 139.40 (CH), 126.3 (CH), 124.1(CH), 88.9
(CH), 87.3 (C), 85.8 (C), 82.0 (C), 61.8 (C), 51.9 (CH2), 36.4 (CH3), 35.7
(CH2), 28.4 (CH3); mp¼197e199 C; IR (thin ﬁlm): 2975, 2796,1702,
1442, 1367, 1352, 1299, 1245, 1158 cm1; HRMS-ESI (m/z) [MþH]þ
calcd for C32H40N4O4I2H 799.1218; found, 799.1224; [a]D23 þ186,
[a]57723 þ195, [a]54623 þ225, [a]43523 þ399, [a]40523 442 (c 0.63, CH2Cl2).
4.4.3. (R,R)-7,70-Diiodo-1,10-dimethyl-1,2,3,8,8a,10,20,30,8,8a0-octahy-
dro-1H,1H0-[3a,3a0]bi[pyrrolo[2,3-b]indolyl] (18). Following the
procedure employed in the meso series,4 neat TMSOTf (4.44 mL,
24.5mmol) was added dropwise to a solution of diiodide E2 (4.45 g,
5.57 mmol) and CH2Cl2 (140 mL). The ﬂask was left open to the air
so that adventitious H2Owould create a small amount of triﬂic acid.
After 3 h, the solution was partitioned between saturated aqueous
NaHCO3 (50 mL) and CH2Cl2 (100 mL). The phases were separated
and the aqueous phase was extracted with CH2Cl2 (3150 mL). The
combined organic layers were dried over MgSO4, ﬁltered, and
concentrated under reduced pressure. The residue was puriﬁed by
ﬂash column chromatography with a gradient elution
(9:1:0/9:1:0.1 CH2Cl2/MeOH/Et3N) to yield 18 as a pale yellow
foam (3.28 g, 99%): 1H NMR (500 MHz, (CD3)2SO, 376 K) d 7.32 (d,
J¼7.9 Hz, 2H), 7.20 (d, J¼7.3 Hz, 2H), 6.37 (t, J¼7.6 Hz, 2H), 5.56 (s,
2H), 4.88 (br s, 2H), 3.04 (s, 1H), 2.78 (dt, J¼2.8, 7.5 Hz, 2H), 2.65 (br
s, 3H), 2.61e2.55 (m, 2H), 2.48e2.45 (m, 2H), 2.01e1.97 (m, 2H); 13C
NMR (125 MHz, (CD3)2SO, 376 K) d 152.3 (C), 135.1 (CH), 133.2 (C),
122.7 (CH), 118.1 (CH), 82.2 (CH), 72.8 (C), 64.3 (C), 50.7 (CH2), 35.2
(CH2), 35.1 (CH3); IR (thin ﬁlm) 3402, 3062, 2845, 2789, 1596, 1470,
1246, 734 cm1; HRMS-ESI (m/z) [MþH]þ calcd for C22H24N4I2H
599.0168; found, 599.0167; mp¼193e195 C; [a]D23 þ363, [a]57723
þ383, [a]54623 þ445, [a]43523 þ909, [a]40523 þ1058 (c 1.1, CH2Cl2).
4.4.4. (R,R)-Dibutenanalide 19. Diiodide 18 (0.300 g, 0.501 mmol)
and stannane 8 (1.31 g, 1.50 mmol) were combined in a round
bottom ﬂask and azeotroped in dry THF (36 mL). The mixturewas
then placed under vacuum (1.0 mmHg) for 30 min and then
pumped into an inert atmosphere (N2) drybox. A stirbar followed
by Pd(PPh3)444 (0.290 g, 0.251mmol), LiCl (0.128 g, 3.01mmol), and
CuCl (0.250 g, 2.51 mmol) were added to the ﬂask and the mixture
was suspended in dry DMSO (17 mL). The ﬂask was capped and
stirred at room temperature in the drybox for 20 h. Upon com-
pletion the ﬂask was removed from the drybox and the black so-
lution was partitioned between 5% v/v aqueous solution of NH4OH
(40 mL) and EtOAc (50 mL) and the aqueous phase was extracted
with EtOAc (330 mL). The combined organic layers were washed
with water (3100 mL) followed by brine (1100 mL). The organic
layer was dried over MgSO4, ﬁltered, and concentrated under re-
duced pressure. The black residue was puriﬁed by ﬂash column
chromatography (10%KF/SiO2:45 100:0 CH2Cl2/98:2 CH2Cl2/MeOH
94:5:1/CH2Cl2/MeOH/NH4OH/88:10:2 CH2Cl2/MeOH/NH4OH)
to provide 19 (0.741g, 98%) as a brown foam: 1H NMR (500 MHz,
CDCl3) d complex due to the presence of multiple conformations on
the NMR time-scale, see copy of spectra; 13C NMR (125MHz, CDCl3)
complex due to the presence of multiple conformations on the
NMR time-scale, see copy of spectra (only major peaks listed)Please cite this article in press as: Canham, S. M.; et al., Tetrahedron (201134.22, 129.7, 128.8, 128.6, 128.1, 128.0, 127.6, 127.4, 117.1, 83.9, 49.3,
35.8, 29.7, 27.8, 26.8, 21.5, 17.5, 13.6; 19F NMR (376 MHz, CDCl3)
73.6; IR (thin ﬁlm) 3415, 3063, 2863, 2791, 1649, 1494, 1455, 1421,
1339, 1207, 1162, 893, 736 cm1; LRMS-ESI (m/z) [MþH]þ calcd for
C74H72N8F6O12S4H 1507.4; found, 1507.4; [a]D23 þ158, [a]57723 þ167,
[a]54623 þ192, [a]43523 þ433, [a]40523 403 (c 0.46, CH2Cl2).
4.4.5. Double enantioselective Heck cyclization of (R,R)-dibutenana-
lide 19. Ditriﬂate 19 (0.200 g, 0.133 mmol) was azeotroped in
benzene (32 mL) in a sealable Schlenk tube and placed under
vacuum (1 mm) for 1 h. To the Schlenk ﬂask was added a stirbar
followed by Pd(OAc)2 (30 mg, 0.13 mmol), (R)-tol-BINAP (0.181 g,
0.266 mmol), and N-Me-p-anisidine (0.143 g, 1.33 mmol). The ﬂask
was evacuated and backﬁlled with N2 (three times). The mixture
was then suspended in 1-methyl-2-pyrrolidinone (4.4 mL)48 and
1,2,2,6,6-pentamethylpiperidine49 (97 mL, 0.53 mmol). The reaction
mixture was degassed using the freezeepumpethaw technique
(three cycles, liquid N2 cooling bath, 0.1 mmHg, backﬁll with N2).
The heterogeneous brown-redmixturewas heated to 80 C for 16 h.
After cooling to room temperature the deep red solution was par-
titioned between a 20% w/w aqueous solution of NaCN (20 mL) and
EtOAc (20 mL). The aqueous layer was extracted with EtOAc
(320 mL). The combined organic layers were washed with water
(340 mL) followed by brine (120 mL). The organic layer was
dried over Na2SO4, ﬁltered, and concentrated under reduced pres-
sure. The residue was puriﬁed by column chromatography (SiO2:
100:0 CH2Cl2/97:3 CH2Cl2/MeOH/94:5:1 CH2Cl2/MeOH/
NH4OH/89:10:1 CH2Cl2/MeOH/NH4OH) to provide eluting ﬁrst
C1-symmetric dioxindole 21 (17.0 mg, 11%) followed by C2-sym-
metric dioxindole 20 (74.0 mg, 46%) as tan foams: (R,R,R,R)-diox-
indole 20: 1H NMR (500 MHz, (CD3)2SO, 376 K) d 7.47 (d, J¼8.3 Hz,
4H), 7.33 (d, J¼8.1 Hz, 4H), 7.31 (dd, J¼7.8, 1.1 Hz, 2H), 7.20 (dd,
J¼6.0, 1.9 Hz, 4H), 7.13 (dd, J¼5.7, 1.9 Hz, 8H), 7.01 (d, J¼7.1 Hz, 2H),
6.95 (d, J¼7.8 Hz, 2H), 6.70 (br d, J¼7.2 Hz, 2H), 6.62 (d, J¼14.3 Hz,
2H), 6.41 (d, J¼7.8 Hz, 2H), 6.14 (t, J¼7.7 Hz, 2H), 5.45 (d, J¼14.3 Hz,
2H), 4.95 (d, J¼15.9 Hz, 2H), 4.90 (d, J¼15.9 Hz, 2H), 4.83 (br s, 4H),
2.90 (s, 6H), 2.63 (br m, 2H), 2.37 (s, 6H), 2.37e2.31 (m, 2H), 2.21 (br
s, 6H), 1.80e1.77 (m, 2H); 13C NMR (125 MHz, (CD3)2SO, 376 K)
d 176.3 (C), 149.3 (C), 143.3 (C), 141.4 (C), 135.7 (C), 135.0 (C), 133.9
(C), 130.4 (CH), 129.4 (CH), 129.2 (CH), 127.8 (CH), 126.5 (CH), 126.3
(CH), 125.9 (CH), 125.2 (CH), 124.7 (CH), 121.9 (CH), 121.7 (CH), 118.6
(C), 117.0 (CH), 109.8 (CH), 109.0 (CH), 82.8 (CH), 78.5 (C), 62.5 (C),
55.7 (C), 50.1 (CH2), 42.5 (CH2), 34.9 (CH2), 34.5 (CH3), 31.8 (CH3),
20.2 (CH3); IR (thin ﬁlm) 3367, 3061, 3032, 2853, 2788, 1700, 1647,
1609, 1466, 1355, 1246, 1159, 743 cm1; HRMS-ESI (m/z) [MþH]þ
calcd for C72H70N8O6S2H 1207.4938; found, 1207.4950; [a]D23 þ28,
[a]57723 þ29, [a]54623 þ34, [a]43523 þ74 (c 1.6, CH2Cl2). (S,R,R,R)-Dioxin-
dole 21: 1H NMR (500 MHz, (CD3)2SO, 376 K) d 7.51 (d, J¼13.6 Hz,
2H), 7.48 (d, J¼13.6 Hz, 2H), 7.44e7.19 (overlapping multiplets,
16H), 7.11e7.03 (m, 6H), 6.98 (d, J¼7.9 Hz,1H), 6.91 (d, J¼7.4 Hz,1H),
6.74 (br d, J¼6.4 Hz, 1H), 6.63 (dd, J¼14.3, 3.7 Hz, 2H), 6.57 (br dd,
J¼10.6, 7.9 Hz, 2H), 6.40 (t, J¼7.5 Hz, 1H), 6.28 (t, J¼7.1 Hz, 1H), 5.45
(d, J¼14.3 Hz,1H), 5.34 (d, J¼14.3 Hz,1H), 5.01 (d, J¼9.1 Hz,1H), 4.97
(s, 2H), 4.85 (d, J¼15.8 Hz, 1H), 4.68 (br s, 1H), 4.44 (br s, 1H), 4.37
(br s,1H), 2.92 (s, 3H), 2.90 (s, 3H), 2.65e2.58 (m,1H), 2.48e2.41 (m,
1H), 2.40 (s, 3H), 2.39 (s, 3H), 2.27e2.26 (m, 2H), 2.22e2.19 (m, 1H),
2.18 (s, 3H), 2.02e1.98 (m, 1H), 1.82 (s, 3H), 1.77 (br dd, J¼11.9,
4.9 Hz, 1H), 1.69e1.66 (m,1H); 13C NMR (125MHz, (CD3)2SO, 376 K)
d 176.3 (C), 175.9 (C), 149.2 (C), 148.4 (C), 143.35 (C), 143.31 (C), 141.4
(C), 141.3 (C), 135.8 (C), 135.6 (C), 134.7 (C), 134.2 (C), 133.9 (C), 133.8
(C), 130.6 (C), 130.5 (C), 129.5 (CH), 129.4 (CH), 129.28 (CH), 129.26
(CH), 127.94 (CH), 127.91 (CH), 127.8 (CH), 127.7 (CH), 127.0 (CH),
126.9 (CH), 126.7 (CH), 126.5 (CH), 126.45 (CH), 126.0 (CH), 125.9
(CH),125.7 (CH),125.6 (CH),124.5 (CH),124.2 (CH),122.3 (CH),122.1
(CH), 121.9 (CH), 119.1 (C), 118.7 (C), 117.2 (CH), 116.7 (CH), 110.2
(CH), 110.0 (CH), 109.0 (CH), 108.9 (CH), 83.2 (CH), 83.0 (CH), 62.25), http://dx.doi.org/10.1016/j.tet.2015.02.080
S.M. Canham et al. / Tetrahedron xxx (2015) 1e13 11(C), 61.9 (C), 55.7 (C), 55.6 (C), 50.4 (CH2), 50.3 (CH2), 42.8 (CH2),
42.6 (CH2), 35.2 (CH2), 35.1 (CH2), 34.5 (CH3), 34.3 (CH3), 31.84
(CH3), 31.78 (CH3), 20.27 (CH3), 20.24 (CH3); IR (thin ﬁlm) 3378,
3060, 2857, 2790, 1703, 1609, 1465, 1356, 1159, 742 cm1; LRMS-ESI
(m/z) [MþH]þ calcd for C72H70N8O6S2H 1207.5; found, 1207.5; [a]D23
þ116, [a]57723 þ121, [a]54623 þ142, [a]43523 þ298, [a]40523 þ276 (c 0.80,
CH2Cl2).
Following the same procedure utilizing (S)-tol-BINAP instead of
(R)-tol-BINAP, dibutenanilide 19 (0.282 mg, 0.187 mmol) was
converted into C2-symmetric dioxindole product 22 and C1-sym-
metric isomer 21. These products were puriﬁed by column chro-
matography (SiO2: 100:0 CHCl3/98:2 CHCl3/MeOH/94:3:1
CHCl3/MeOH/NH4OH/94:5:1 CHCl3/MeOH/NH4OH) to elute ﬁrst
C2-symmetric 22 (123 mg, 55%) followed by C1-symmetric 21
(87.0 mg, 39%) as tan foams. (S,R,R,S)-dioxindole 22: 1H NMR
(500 MHz, (CD3)2SO, 376 K) d 7.50 (d, J¼8.2 Hz, 4H), 7.40 (t,
J¼6.3 Hz, 8H), 7.32 (t, J¼6.9 Hz, 4H), 7.28 (dt, J¼1.9, 9.0 Hz, 4H), 7.07
(dd, 7.2, 14.8 Hz, 8H), 6.90 (d, J¼7.7 Hz, 2H), 6.68 (d, J¼7.9 Hz, 2H),
6.64 (d, J¼14.3 Hz, 2H), 6.44 (t, J¼7.8 Hz, 2H), 5.34 (d, J¼14.3 Hz,
2H), 4.97 (d, J¼15.8 Hz, 2H), 4.95 (d, J¼15.7 Hz, 2H), 4.39 (br d,
12.6 Hz, 2H), 2.90 (s, 6H), 2.40 (m, 8H), 2.25e2.19 (m 2H), 2.01e1.90
(m, 2H), 1.80 (s, 6H), 1.65e1.62 (m, 2H); 13C NMR (125 MHz,
(CD3)2SO, 376 K) d 176.0 (C), 148.6 (C), 143.4 (C), 141.3 (C), 135.7 (C),
133.8 (C), 130.5 (CH), 129.6 (CH), 129.3 (CH), 127.9 (CH), 127.7 (CH),
127.0 (CH), 126.9 (CH), 126.5 (C), 126.99 (CH), 125.95 (CH), 124.2
(CH), 122.7 (CH), 122.1 (CH), 118.8 (C), 116.8 (CH), 110.2 (CH), 108.9
(CH), 83.3 (CH), 61.9 (C), 55.7 (C), 50.6 (CH2), 42.8 (CH2), 35.3 (CH2),
34.2 (CH3), 31.8 (CH3), 20.3 (CH3); IR (thin ﬁlm) 3417, 3376, 3061,
3032, 2867, 2791, 2244, 1708, 1650, 1609, 1485, 1465, 1357, 1247,
1160, 732 cm1; LRMS-ESI (m/z) [MþH]þ calcd for C72H70N8O6S2H
1207.5; found, 1207.5; [a]D23 þ147, [a]57723 þ156, [a]54623 þ184, [a]43523
þ379, [a]40523 þ201 (c 0.81, CH2Cl2).4.5. Optimized general procedure for hydrogenation of the
enesulfonamide side chains of the dioxindole Heck products
4.5.1. Synthesis of the tetrahydro derivative of 20. A solution of 20
(140 mg, 0.116 mmol) in warm EtOH (4.0 mL) was added to a glass
sleeve containing Pd(OH)2/C (0.28 g, 20 wt %), K2CO3 (130 mg,
0.928 mmol), and a stirbar. The sleeve was ﬁtted inside a pressure
reactor (Parr bottle 250mL) and sealed. The Parr bottle was charged
with hydrogen gas (1000 psi) and heated to 80 C for 24 h. After
cooling to room temperature and venting the mixture was ﬁltered
through Celite and the ﬁlter cake was washed with CHCl3 satu-
rated with NH3 (20 mL). The washes were concentrated to afford
the tetrahydro derivative of 20 (139mg, 99%) as a colorless foam. An
analytical sample was obtained by column chromatography (SiO2:
100:0 CH2Cl2/97:3 CH2Cl2/MeOH/94:5:1 CH2Cl2/MeOH/
NH4OH/89:10:1 CH2Cl2/MeOH/NH4OH) to provide 121 mg (96%)
of 21 as a colorless foam: 1H NMR (500MHz, (CD3)2SO, 396 K) d 7.54
(d, J¼8.2 Hz, 4H), 7.31 (overlapping signals d and m, d; J¼8.0 Hz,
8H), 7.18 (t, J¼7.2 Hz, 2H), 7.14 (t, J¼7.4 Hz, 2H), 7.10 (d, J¼7.2 Hz,
4H), 7.02 (t, J¼6.8 Hz, 2H), 6.96 (t, J¼7.4 Hz, 4H), 6.89 (d, J¼7.9 Hz,
2H), 6.77 (d, J¼7.5 Hz, 2H), 6.33 (d, J¼7.7 Hz, 2H), 6.04 (t, J¼7.6 Hz,
2H), 5.77 (br s, 2H), 4.97 (d, J¼15.8 Hz, 2H), 4.75 (d, J¼15.8 Hz, 2H),
3.07e3.01 (m, 2H), 2.91e2.86 (m, 4H), 2.81 (br s, 4H), 2.63 (s, 6H),
2.38 (s, 6H), 2.37 (s, 6H), 2.32e2.23 (m, 2H), 1.93e1.87 (m, 2H), 1.26
(br s, 2H); 13C NMR (125MHz, (CD3)2SO, 396 K) d 177.2 (C),149.6 (C),
142.3 (C), 141.9 (C), 135.3 (C), 134.6 (C), 129.4 (C), 128.8 (CH), 127.62
(CH), 127.57 (CH), 126.3 (CH), 126.2 (CH), 126.1 (CH), 124.7 (CH),
124.5 (CH), 121.7 (CH), 121.4 (CH), 118.0 (C), 117.7 (C), 117.3 (CH),
108.9 (CH), 82.8 (CH), 62.4 (C), 53.8 (C), 50.1 (CH2), 45.5 (CH2), 42.5
(CH2), 34.7 (CH2), 34.6 (CH2), 33.9 (CH3), 30.0 (CH3), 20.0 (CH3); IR
(thin ﬁlm) 3334, 3060, 3031, 2857, 2788, 1695, 1611 cm1; HRMS-
ESI (m/z) [MþH]þ calcd for C72H74N8O6S2H 1211.5251; found,
Please cite this article in press as: Canham, S. M.; et al., Tetrahedron (2011211.5251; [a]D23 e40, [a]57723 e43, [a]54623 e51, [a]43523 e102, [a]40523
e121 (c 1.5, CH2Cl2).
4.5.2. Tetrahydro derivative of 22. Following the optimized general
procedure for the hydrogenation of the enesulfonamide side
chains, 125 mg of 22 yielded 121 mg (96%) of the tetrahydro de-
rivative of 22: 1H NMR (500 MHz, (CD3)2SO, 396 K) d 7.51 (d,
J¼7.9Hz, 4H), 7.38e7.34 (m, 8H), 7.30e7.27 (m, 8H), 7.17 (d,
J¼7.0 Hz, 2H), 7.10 (t, J¼7.4 Hz, 2H), 7.03 (d, J¼7.6 Hz, 2H), 6.94 (d,
J¼6.8 Hz, 2H), 6.72 (d, J¼7.8 Hz, 2H), 6.42 (t, J¼7.3 Hz, 2H), 5.23 (s,
2H), 4.95 (d, J¼16.4 Hz, 2H), 4.89 (d, J¼15.3 Hz, 2H), 4.41 (s, 2H),
2.95e2.91 (m, 2H), 2.84e2.80 (m, 4H), 2.65 (s, 6H), 2.49e2.42 (m,
2H), 2.39 (s, 6H), 2.36e2.31 (m, 2H), 2.27e2.24 (m, 2H), 2.14e1.11
(m, 2H), 2.00 (s, 6H), 1.75e1.71 (m, 2H); 13C NMR (125 MHz,
(CD3)2SO, 396 K) d 177.0 (C), 148.9 (C), 142.3 (C), 141.8 (C), 135.6 (C),
134.8 (C), 129.8 (C), 128.8 (CH), 127.8 (CH), 127.6 (CH), 126.9 (CH),
126.7 (CH),126.2 (CH),125.1 (CH),124.0 (CH),122.8 (CH),121.9 (CH),
117.8 (C), 116.8 (CH), 116.7 (C), 108.8 (CH), 83.8 (CH), 61.7 (C), 53.3
(C), 50.9 (CH2), 45.2 (CH2), 42.9 (CH2), 35.0 (CH3), 34.8 (CH3), 33.9
(CH2), 31.5 (CH2), 20.0 (CH3); IR (thin ﬁlm) 3320, 3057, 3033, 2851,
2790, 1692, 1610 cm1; LRMS-ESI (m/z) [MþH]þ calcd for
C72H74N8O6S2H 1211.5; found, 1211.5; [a]D23 þ254, [a]57723 þ269,
[a]54623 þ312, [a]43523 þ625 (c 1.1, CH2Cl2).
4.5.3. Tetrahydro derivative of 21. Following the optimized general
procedure for the hydrogenation of the enesulfonamide side
chains, 230 mg of 21 yielded 224 mg (97%) of tetrahydro derivative
of 21: 1H NMR (500 MHz, (CD3)2SO, 396 K) d 7.50 (d, J¼8.2 Hz, 2H),
7.48 (d, J¼8.2 Hz, 2H), 7.37 (d, J¼7.1 Hz, 2H), 7.32 (d, J¼8.2 Hz, 4H),
7.30e7.23 (m, overlapping signals, 8H), 7.22 (d, J¼7.9 Hz, 2H),
7.16e7.07 (m, 4H), 7.02 (d, J¼7.8 Hz, 1H), 6.98 (d, J¼7.8 Hz, 1H), 6.95
(d, J¼7.3 Hz, 1H), 6.80 (d, J¼7.3 Hz, 1H), 6.62 (d, J¼7.7 Hz, 1H), 6.59
(d, J¼7.9 Hz,1H), 6.36 (t, J¼7.5 Hz,1H), 6.27 (t, J¼7.4 Hz,1H), 5.44 (d,
J¼3.9 Hz, 1H), 5.18 (s, 1H), 4.96 (d, J¼15.6 Hz, 1H), 4.90 (s, 2H), 4.89
(d, J¼15.4 Hz, 1H), 4.70 (br s, 1H), 4.43 (br s, 1H), 3.03e2.98 (m, 1H),
2.97e2.89 (m, 2H), 2.80 (br s, 3H), 2.68e2.61 (m, 1H), 2.66 (s, 3H),
2.65 (s, 3H), 2.44e2.40 (m, 2H), 2.39 (s, 3H), 2.37 (s, 3H), 2.34e2.31
(m, 2H), 2.30 (s, 3H), 2.28e2.25 (m, 2H), 2.15e2.10 (m, 1H), 2.00 (s,
3H), 1.84e1.81 (m, 1H), 1.75e1.72 (m, 1H); 13C NMR (125 MHz,
(CD3)2SO, 396 K) d 177.2 (C), 176.9 (C), 149.5 (C), 148.8 (C), 142.30 (C,
overlapping signal), 142.30 (C, overlapping signal), 141.89 (C),
141.86 (C), 135.63 (C), 135.57 (C), 135.2 (C), 134.8 (C), 134.7 (C), 134.5
(C), 129.8 (C), 129.6 (C), 128.85 (CH, overlapping signal), 128.85 (CH,
overlapping signal), 127.76 (CH, overlapping signal), 127.67 (CH,
overlapping signal), 127.71 (CH), 127.6 (CH), 126.9 (CH), 126.7 (CH),
126.6 (CH), 126.3 (CH), 126.2 (CH), 126.1 (CH), 124.9 (CH), 124.7
(CH), 124.4 (CH), 124.0 (CH), 122.3 (CH), 122.0 (CH), 121.84 (CH),
121.77 (CH), 118.5 (C), 117.7 (CH), 117.4 (C), 116.8 (CH), 108.8 (CH),
108.7 (CH), 83.6 (CH), 82.9 (CH), 62.3 (C), 61.9 (C), 53.7 (C), 53.3 (C),
50.6 (CH2), 50.3 (CH2), 45.4 (CH2), 45.2 (CH2), 42.9 (CH2), 42.8 (CH2),
35.0 (CH2), 34.9 (CH2), 34.8 (CH3), 34.7 (CH3), 33.92 (CH3), 33.87
(CH3), 31.3 (CH2), 30.6 (CH2), 20.05 (CH3), 20.03 (CH3); IR (thin ﬁlm)
3334, 3058, 2852, 2789, 1693, 1610 cm1; LRMS-ESI (m/z) [MþH]þ
calcd for C72H74N8O6S2H 1211.5; found, 1211.5; [a]D23 þ148, [a]57723
þ155, [a]54623 þ180, [a]43523 þ360, [a]40523 þ410 (c 0.87, CH2Cl2).
4.6. Optimized general procedure for reductive cyclization to
form dodecacyclic alkaloid products
4.6.1. Preparation of (R,R,R,R)-quadrigemine 7. Caution!!! Ammonia
gas is toxic and should only be used in a well-ventilated fume hood.
Ammonia was condensed in a two-neck ﬂask cooled to 78 C and
ﬁtted with a cold ﬁnger ﬁlled with dry ice and isopropanol. After
condensingw20 mL NH3(l) a small piece of sodium (w25 mg) was
added to provide a deep blue color. Using a wide-bore cannula
approximately 10 mL of ammonia was distilled into another two-5), http://dx.doi.org/10.1016/j.tet.2015.02.080
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dry ice and isopropanol. The tetrahydro derivative of 20 (68.0 mg,
0.056 mmol) in dry THF (3 mL) was added to the liquid NH3. tert-
Butanol (42 mL, 0.448 mmol) was added followed by slow addition
of small pieces of sodium metal (65 mg, 2.8 mmol). The heteroge-
neous solution was stirred vigorously at 78 C as the solution
slowly changed from clear yellow, green-brown, to blue. After
persistence of the blue color for 20 min the reaction was quenched
at 78 C by slowly adding solid NH4Cl (w190 mg). The blue color
disappeared and a cloudy colorless precipitate formed. The ﬂask
was allowed to slowly warm to room temperature while open to
the atmosphere and the ammonia permitted to evaporate. Water
(20 mL) was added to the heterogeneous mixture and extracted
with CHCl3 (saturated with NH3; 330 mL). The combined organic
layers were washed with brine (20 mL), dried over Na2SO4, ﬁltered,
concentrated under reduced pressure, and the residue was puriﬁed
by reverse-phase HPLC to yield (R,R,R,R)-quadrigemine 7 (8.8 mg,
23% from 20): Analytical reverse-phase HPLC (Zorbax Extend C18,
2504.6 mm), 72:28e>85:15 MeOH/H2O (1% NH4OH) over 40min,
1.0 mL/min, UV detection at 254 nm (tR¼24.8 min); 1H NMR
(500 MHz, (CD3)2SO, 376 K) d 6.93 (app t, J¼7.1 Hz, 2H), 6.87 (d,
J¼7.4 Hz, 2H), 6.70e6.67 (m, 3H), 6.57 (app t, J¼7.0 Hz, 2H), 6.50 (d,
J¼7.7 Hz, 2H), 6.20 (br app t, J¼7.7 Hz, 1H), 5.81 (br s, 1H), 5.75 (br s,
1H), 4.77 (br s, 1H), 4.71 (br s, 2H), 3.89e2.82 (m, 7H), 2.61 (br s,
1H), 2.41 (s, 7H), 2.36 (s, 5H), 2.26e2.23 (m, 2H), 1.83e1.79 (m, 3H),
1.34e1.25 (m, 6H), 0.85 (app t, J¼7.1 Hz, 2H); 1H NMR (500 MHz,
C6D6, 345 K) d 7.10 (d, J¼6.9 Hz, 2H), 7.08 (d, J¼7.5 Hz, 1H), 7.01 (t,
J¼7.6 Hz, 2H), 6.96 (br s, 1H), 6.76 (t, J¼7.3 Hz, 2H), 6.48 (br s, 1H),
6.42 (d, J¼7.5 Hz, 1H), 5.92 (s, 1H), 5.05 (s, 1H), 4.86 (s, 1H), 3.46 (br
s, 1H), 3.14e3.10 (m, 1H), 2.78 (t, J¼7.8 Hz, 2H), 2.70e2.68 (m, 3H),
2.60e2.56 (m, 3H), 2.55e2.51 (m, 3H), 2.49 (s, 3H), 2.40 (br s, 5H),
2.25 (s, 4H), 1.94 (t, J¼8.1 Hz, 4H), 1.85 (dd, J¼5.0 & 11.1 Hz, 1H),
1.32e1.28 (m, 3H); 13C NMR (125 MHz, C6D6, 345 K) d 151.8 (C),
150.8 (C), 133.7 (C), 126.5 (CH), 125.7 (CH), 119.6 (CH), 117.4 (CH),
109.8 (CH), 88.2 (CH), 84.8 (CH), 64.3 (C), 61.9 (C), 53.0 (CH2), 51.8
(CH2), 48.9 (CH), 39.3 (CH2), 37.4 (CH2), 36.2 (CH3), 35.9 (CH3), 30.7
(C), 29.5 (CH), 18.1 (C); IR (thin ﬁlm) 3379, 3270, 3053, 2930, 2855,
2789, 1604, 1485, 1466, 1248, 1153, 1036, 908, 737 cm1; HRMS-ESI
(m/z) [MþH]þ calcd for C44H50N8H 691.4236; found, 691.4237; [a]D23
þ277, [a]57723 þ283, [a]54623 þ328, [a]43523 þ656 (c 0.20, EtOH).
4.6.2. (S,R,R,S)-Quadrigemine (5). Following the optimized general
for the reductive cyclization, the tetrahydro derivative of 22 (71mg,
0.059 mmol) was converted to 5 (11.9 mg, 29%): Analytical reverse-
phase HPLC (Zorbax Extend C18, 2504.6 mm), 72:28 to >85:15
MeOH/H2O (1% NH4OH) over 40 min, 1.0 mL/min, UV detection at
254 nm: (tR¼29.4 min); 1H NMR (500 MHz, (CD3)2SO, 376 K)
d 6.98e6.94 (overlapping doublets, 6H), 6.86 (d, J¼7.2 Hz, 2H), 6.61
(t, J¼7.1 Hz, 2H), 6.56 (d, J¼7.6 Hz, 2H), 6.37 (t, J¼7.5 Hz, 2H), 6.05
(br s, 2H), 5.88 (br s, 2H), 4.84 (s, 2H), 4.72 (s, 2H), 2.94e2.90 (m,
8H), 2.76e2.69 (m, 2H), 2.41 (s, 6H), 2.37e2.34 (m, 2H), 2.13 (s, 6H),
1.90e1.88 (m, 2H),1.78e1.75 (m, 2H); 13C NMR (125MHz, (CD3)2SO,
376 K) d 150.9 (C), 148.9 (C), 132.8 (C), 131.7 (C), 127.6 (CH), 126.8
(CH), 124.5 (CH), 123.8 (CH), 122.9 (C), 116.6 (CH), 115.0 (CH), 107.5
(CH), 85.5 (CH), 83.2 (CH), 61.9 (C), 59.6 (C), 51.2 (CH2), 50.9 (CH2),
37.9 (CH2), 35.4 (CH2), 34.8 (CH3), 34.7 (CH3); IR (thin ﬁlm) 3379,
3245, 3050, 2858, 2791, 1683, 1604, 1486 cm1; HRMS-ESI (m/z)
[MþH]þ calcd for C44H50N8H 691.4236; found, 691.4223; [a]D23
þ279, [a]57723 þ289, [a]54623 þ332, [a]43523 þ690 (c 0.27, EtOH).
4.6.3. (S,R,R,R)-Quadrigemine 6. Following the optimized general
procedure for the reductive cyclization, the tetrahydro derivative of
21 (73mg, 0.06mmol) was converted to 6 (11.9mg, 29%): Analytical
reverse-phase HPLC (Zorbax Extend C18, 2504.6 mm), 72:28 to
>85:15 MeOH/H2O (1% NH4OH) over 40 min, 1.0 mL/min, UV de-
tection at 254 nm: (tR¼27.3 min); 1H NMR (500 MHz, (CD3)2SO,
Please cite this article in press as: Canham, S. M.; et al., Tetrahedron (201376 K) d 6.98 (d, J¼7.1 Hz, 2H), 6.95 (d, J¼3.3 Hz, 1H), 6.93 (d,
J¼7.2 Hz, 3H), 6.83 (d, J¼7.2 Hz, 1H), 6.79 (t, J¼8.1 Hz, 2H),
6.62e6.57 (m, 2H), 6.54 (dd, J¼5.7, 7.1 Hz, 2H), 6.34 (t, J¼7.2 Hz, 1H),
6.28 (t, J¼7.3 Hz, 1H), 6.00 (s, 1H), 5.86 (s, 1H), 5.82 (s, 1H), 5.75 (s,
1H), 4.80 (s, 2H), 4.69 (br s, 1H), 4.56 (br s, 1H), 2.68e2.61 (m, 3H),
2.47e2.43 (m, 5H), 2.41 (s, 3H), 2.39 (s, 3H), 2.33 (s, 3H), 2.31e2.26
(m, 2H), 2.14e2.11 (m,1H), 2.10 (s, 3H), 1.89e1.82 (m, 3H), 1.77e1.73
(m, 1H); 13C NMR (125 MHz, (CD3)2SO, 376 K) d 151.9 (C), 149.9 (C),
127.9 (C), 125.7 (C), 117.7 (CH), 117.5 (C), 116.4 (CH), 116.0 (CH), 108.5
(CH), 87.1 (CH), 86.5 (CH), 84.3 (CH), 83.9 (CH), 70.5 (CH), 63.0 (C),
60.7 (C), 52.3 (CH2), 51.8 (CH2), 39.0 (CH2), 38.9 (CH2), 36.2 (CH3),
35.9 (CH3); IR (thin ﬁlm) 3378, 3055, 2852, 2791, 1698, 1603, 1486,
1456 cm1; HRMS-ESI (m/z) [MþH]þ calcd for C44H50N8H 691.4236;
found, 691.4237; [a]D23 þ347, [a]57723 þ367, [a]54623 þ435, [a]43523 þ854
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